Study: Cannabis against Fabry disease pain.
A research project supported by the Swiss National Science Foundation.
>> Participants wanted for study.

New approaches in research based on MOOS. The company GREENOVATION is working intensively on the production of enzymes based on moss as a starting material!

Greenovation is developing next-generation therapeutics using its proprietary Bryo technology platform with the goal of optimizing the production of highly efficient glycoproteins. The pipeline includes molecules for the treatment of Fabry disease, C3 glomerulopathy (a group of rare kidney diseases in which complement factors in the kidney lead to a disease with proteinuria and renal insufficiency) and Pompe disease (this is a glycogen storage disease and also belongs to the group of lysosomal storage diseases). The first phase of clinical trials for Moss-aGal - an enzyme replacement therapy for Fabry disease - was successfully completed at the end of 2017.

CONTACT
Karin Heidenreich
Director Medical Alliance
Tel. + 49 761 470 99 0
bd@greenovation.com
www.greenovation.com